A decade of fragment-based drug design: strategic advances and lessons learned

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1

2001 • 16,438 citations

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

1997 • 9,861 citations

Drug-like properties and the causes of poor solubility and poor permeability

2000 • 3,405 citations

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

2005 • 3,292 citations

Discovering High-Affinity Ligands for Proteins: SAR by NMR

1996 • 1,986 citations

Virtual screening of chemical libraries

2004 • 1,314 citations

A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening

2002 • 1,039 citations

NMR Spectroscopy Techniques for Screening and Identifying Ligand Binding to Protein Receptors

2003 • 971 citations

Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery

2001 • 849 citations

Is There a Difference between Leads and Drugs? A Historical Perspective

2001 • 757 citations

The role of Bcl-2 family members in tumorigenesis

2003 • 536 citations

Functionality maps of binding sites: A multiple copy simultaneous search method

1991 • 535 citations

Ligand efficiency indices as guideposts for drug discovery

2005 • 516 citations

Druggability Indices for Protein Targets Derived from NMR-Based Screening Data

2005 • 508 citations

Knockouts model the 100 best-selling drugs—will they model the next 100?

2002 • 392 citations

Dynamic Combinatorial Chemistry

2001 • 391 citations

Tethering: Fragment-Based Drug Discovery

2004 • 374 citations

Novel p-Arylthio Cinnamides as Antagonists of Leukocyte Function-Associated Antigen-1/Intracellular Adhesion Molecule-1 Interaction. 2. Mechanism of Inhibition and Structure-Based Improvement of Pharmaceutical Properties

2001 • 338 citations

Fragment-based lead discovery: leads by design

2005 • 337 citations

Discovering novel ligands for macromolecules using X-ray crystallographic screening

2000 • 313 citations

Theory and Applications of NMR-Based Screening in Pharmaceutical Research

2004 • 312 citations

Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR

1997 • 309 citations

Virtual Exploration of the Small‐Molecule Chemical Universe below 160 Daltons

2005 • 307 citations

Discovery of a Potent Inhibitor of the Antiapoptotic Protein Bcl-x_L from NMR and Parallel Synthesis

2005 • 281 citations

Recent advances in matrix metalloproteinase inhibitor research

1996 • 279 citations

Can cell systems biology rescue drug discovery?

2005 • 275 citations

The SHAPES strategy: an NMR-based approach for lead generation in drug discovery

1999 • 270 citations

Fragment-Based Drug Design: How Big Is Too Big?

2006 • 264 citations

Integrating virtual screening in lead discovery

2004 • 247 citations

Critical review of the role of HTS in drug discovery

2006 • 238 citations

Discovery of a Potent Small Molecule IL-2 Inhibitor through Fragment Assembly

2003 • 234 citations

NMR-based screening in drug discovery

1999 • 227 citations

ALARM NMR: A Rapid and Robust Experimental Method To Detect Reactive False Positives in Biochemical Screens

2004 • 220 citations

Discovery of a Potent, Selective Protein Tyrosine Phosphatase 1B Inhibitor Using a Linked-Fragment Strategy

2003 • 215 citations

A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design

2005 • 203 citations

Rescuing drug discovery: in vivo systems pathology and systems pharmacology

2005 • 200 citations

Library Design for Fragment Based Screening

2005 • 189 citations

Identification of Novel p38α MAP Kinase Inhibitors Using Fragment-Based Lead Generation

2004 • 178 citations

Rediscovering the sweet spot in drug discovery

2003 • 177 citations

Fragment‐based Approaches in Drug Discovery

2006 • 175 citations

New assay technologies for high-throughput screening

1998 • 150 citations

Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits

2006 • 148 citations

TINS, Target Immobilized NMR Screening: An Efficient and Sensitive Method for Ligand Discovery

2005 • 138 citations

Structural Biology and Drug Discovery

2006 • 131 citations

Recent developments in dynamic combinatorial chemistry

2002 • 129 citations

Efficient synthetic inhibitors of anthrax lethal factor

2005 • 126 citations

Diffusion-Edited NMR−Affinity NMR for Direct Observation of Molecular Interactions

1997 • 118 citations

A General NMR Method for Rapid, Efficient, and Reliable Biochemical Screening

2003 • 116 citations

NMR-Based Screening with Competition Water−Ligand Observed via Gradient Spectroscopy Experiments: Detection of High-Affinity Ligands

2002 • 109 citations

Components of Successful Lead Generation

2005 • 108 citations

Identification of Potent and Selective Small-Molecule Inhibitors of Caspase-3 through the Use of Extended Tethering and Structure-Based Drug Design

2002 • 104 citations

Characterization of protein-ligand interaction sites using experimental and computational methods.

2006 • 101 citations

Phenoxyphenyl SulfoneN-Formylhydroxylamines (Retrohydroxamates) as Potent, Selective, Orally Bioavailable Matrix Metalloproteinase Inhibitors

2001 • 97 citations

SAR and X-ray. A New Approach Combining Fragment-Based Screening and Rational Drug Design: Application to the Discovery of Nanomolar Inhibitors of Src SH2

2002 • 89 citations

Structure–activity relationships by interligand NOE-based design and synthesis of antiapoptotic compounds targeting Bid

2006 • 88 citations

Key Aspects of the Novartis Compound Collection Enhancement Project for the Compilation of a Comprehensive Chemogenomics Drug Discovery Screening Collection

2005 • 77 citations

In silico fragment-based discovery of indolin-2-one analogues as potent DNA gyrase inhibitors

2005 • 77 citations

Discovery of novel inhibitors of Bcl-xL using multiple high-throughput screening platforms

2004 • 70 citations

Discovery of Potent Inhibitors of Dihydroneopterin Aldolase Using CrystaLEAD High-Throughput X-ray Crystallographic Screening and Structure-Directed Lead Optimization

2004 • 70 citations

Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach

2006 • 66 citations

Design of Adenosine Kinase Inhibitors from the NMR-Based Screening of Fragments

2000 • 64 citations

Integration of NMR and High-Throughput Screening

2002 • 60 citations

Theoretical Analysis of the Inter-Ligand Overhauser Effect: A New Approach for Mapping Structural Relationships of Macromolecular Ligands

1999 • 51 citations

Requirements for Specific Binding of Low Affinity Inhibitor Fragments to the SH2 Domain of^pp60Src Are Identical to Those for High Affinity Binding of Full Length Inhibitors

2003 • 49 citations

NMR spectroscopy as a tool for structure-based drug design

1998 • 49 citations

Fragment screening by biochemical assay

2006 • 47 citations

The multiple orthogonal tools approach to define molecular causation in the validation of druggable targets

2004 • 43 citations

Challenges and prospects for computational aids to molecular diversity

1996 • 29 citations

Leveraging structural approaches: applications of NMR-based screening and X-ray crystallography for inhibitor design

2003 • 26 citations

Site-directed structure generation by fragment-joining

1995 • 26 citations

Genomics: success or failure to deliver drug targets?

2005 • 25 citations

Structural analysis of caspase-1 inhibitors derived from Tethering

2005 • 24 citations

Fragmentary Solutions Astex Therapeutics Puts the Pieces Together

2006 • 3 citations